Quantbot Technologies LP Invests $945,000 in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Quantbot Technologies LP acquired a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 25,454 shares of the company's stock, valued at approximately $945,000. Quantbot Technologies LP owned approximately 0.05% of Amphastar Pharmaceuticals at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Smartleaf Asset Management LLC increased its position in shares of Amphastar Pharmaceuticals by 222.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock valued at $26,000 after purchasing an additional 493 shares during the period. Parkside Financial Bank & Trust boosted its position in shares of Amphastar Pharmaceuticals by 806.5% during the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company's stock valued at $36,000 after purchasing an additional 871 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. grew its stake in shares of Amphastar Pharmaceuticals by 53.4% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company's stock worth $56,000 after purchasing an additional 398 shares during the last quarter. TD Private Client Wealth LLC raised its holdings in shares of Amphastar Pharmaceuticals by 22.7% in the 4th quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company's stock worth $78,000 after purchasing an additional 388 shares in the last quarter. Finally, KBC Group NV lifted its stake in Amphastar Pharmaceuticals by 43.1% during the fourth quarter. KBC Group NV now owns 2,159 shares of the company's stock valued at $80,000 after purchasing an additional 650 shares during the last quarter. Institutional investors and hedge funds own 65.09% of the company's stock.

Remove Ads

Amphastar Pharmaceuticals Trading Down 0.2 %

Shares of Amphastar Pharmaceuticals stock traded down $0.07 during trading on Friday, hitting $28.43. The stock had a trading volume of 386,842 shares, compared to its average volume of 438,844. Amphastar Pharmaceuticals, Inc. has a 1 year low of $25.89 and a 1 year high of $53.96. The stock has a 50 day simple moving average of $31.07 and a 200 day simple moving average of $39.93. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The company has a market capitalization of $1.35 billion, a PE ratio of 9.48, a P/E/G ratio of 2.19 and a beta of 0.77.

Insider Activity

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the sale, the chief financial officer now owns 97,363 shares in the company, valued at $2,681,377.02. This represents a 4.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 27.10% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Separately, Piper Sandler dropped their price target on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a report on Friday, March 21st.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.